In contrast, PDK1 activation can be suppressed by PPARγ-coactivator-1α (PGC-1α), although PPARγ appears to be upregulated in HCC cells and human HCC tissues resistant to Sorafenib [127]. Here, PPARGC1A is linked to hepatocellular carcinoma.